Login / Signup

Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.

Andrew X ZhuRyan David NippRichard S FinnPeter R GalleJosep M LlovetJean-Frederic BlancTakuji OkusakaIan ChauDavid CellaAllicia GirvanJonathon GableLee BowmanChunxiao WangYanzhi HsuPaolo B AbadaMasatoshi Kudo
Published in: ESMO open (2021)
NCT01140347; NCT02435433, NCT02435433.
Keyphrases
  • patient reported outcomes
  • clinical trial
  • open label
  • double blind
  • phase ii
  • study protocol
  • randomized controlled trial